← SynDRA
ELAGOLIX
SynDRA canonical compound SYN0023682 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | GNRH1 | GNRHR |
|---|
| Mechanism of action | gonadotropin releasing factor hormone receptor antagonist |
|---|
All known targets
Mechanisms of action (all sources)
- GNRHR ANTAGONIST
- Gonadotropin-releasing hormone receptor antagonist
- gonadotropin releasing factor hormone receptor antagonist
Drug classes
- Gonadotropin Releasing Hormone Receptor Antagonists
- Gonadotropin Releasing Hormone Receptor Antagonist
- Cytochrome P450 2C19 Inhibitors
- P-Glycoprotein Inhibitors
- Cytochrome P450 3A Inducers
ATC classes
- H01C · HYPOTHALAMIC HORMONES
Cross-references
Synonyms
- elagolix sodium
- orilissa
- NBI-56418
- BT-620
- UNII-5B2546MB5Z
- NBI 56418
- 5B2546MB5Z
- NBI56418
- Elagolix [USAN:INN]
- Orilissa
- ELA gOLIX
- Elagolix (USAN/INN)
- SCHEMBL1642523
- GTPL8362
- CHEMBL1208155
- DTXSID40232348
- ABT-620
- 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoic acid
- EX-A1765
- BCP08827
- ZINC49888891
- CS-5329
- SB16700
- DB11979
- compound 10b [PMID 19006286]
- HY-14789
- AN-27202
- D09335
- Z-3253
- 153E876
- Butanoic acid, 4-(((1R)-2-(5-(2-flu
- elagolixum
- RefChem:58959
- DTXCID40154839
- H01CC03
- (R)-Elagolix
- Elagolix [USAN]
- Elagolix?
Reported adverse events
- Headache
- Suicidal ideation
- Alopecia
- Anxiety
- Arthralgia
- Completed suicide
- Depressed mood
- Depression
- Fatigue
- Hypersensitivity
- Insomnia
- Mood altered
Look up ELAGOLIX in the interactive SynDRA portal →